Close Menu

NEW YORK – Merck announced on Tuesday that the US Food and Drug Administration has accepted its supplemental biologics license application for the accelerated approval of pembrolizumab (Keytruda) as a monotherapy for previously treated cancer patients who have a high tumor mutational burden.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.